clairop

Remicade Pros and Cons for Crohn's Disease

Remicade (infliximab) can bring Crohn's into remission and close fistulas, but carries boxed warnings for infection and lymphoma. Evidence, both sides.

Clairop Team23 min read

Photo: Annie Spratt / Unsplash

The short answer

Remicade (infliximab) is an anti-TNF infusion that has the longest trial record in Crohn's disease, including for fistulas. The cons are a boxed warning for serious infection and lymphoma, infusion reactions, regular infusions, and loss of response in many people over time. Combination therapy, drug-level testing and biosimilars change the picture. Whether it fits you is a decision for your gastroenterologist.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Remicade (infliximab) is an intravenous anti-TNF biologic: it blocks tumor necrosis factor, a signaling protein that drives inflammation in Crohn's disease. On the plus side it has the longest trial record in Crohn's, including for fistulas. On the minus side it has a boxed warning for serious infections and malignancy, can cause infusion reactions, needs regular infusions, and stops working for a lot of people over time.

This guide lays out both columns with the numbers behind them, using the US prescribing information, the landmark trials and the AGA guideline, with every figure linked to its source. It describes options and evidence. It does not tell you to start, stay on, stop or switch anything, because that belongs to the people who know your disease. The labels and guideline used here are US ones. Our questions to ask about Crohn's treatment post covers what to bring to that conversation.

What are the Remicade pros and cons at a glance?

The short version is strong trial evidence and fistula data on one side, and a boxed warning, infusion burden and fading response on the other. Each row is unpacked with sources below.

ProsCons
Strong randomized evidence for inducing and maintaining remissionBoxed warning: serious infections (TB, fungal, sepsis) and malignancy
Randomized fistula evidence; AGA strong recommendation for perianal fistulasRare fatal lymphoma (HSTCL), mostly with azathioprine or 6-MP in young males
Helps some people reduce steroid useAbout 20% had an infusion reaction in label studies
Supervised infusions every 8 weeksInfusion visits of at least 2 hours, with premedication in some units
Longest safety follow-up; biosimilars availableAntibodies and loss of response: 60% of initial responders by year 3 in PANTS
Combination with a thiopurine can improve resultsCombination carries higher lymphoma risk in a large cohort

What is Remicade and how does it treat Crohn's disease?

Remicade is the brand name of infliximab, a lab-made antibody that binds tumor necrosis factor alpha (TNF) and stops it triggering inflammation in the gut wall. In the US label, adults with moderate to severe or fistulizing Crohn's get it by IV infusion at weeks 0, 2 and 6, then every 8 weeks, and the infusion runs for at least 2 hours (Remicade label). For what happens after an anti-TNF stops working, see how often do people switch biologics for Crohn's?. If several have already failed, see what to do when all biologics fail for Crohn's.

Infliximab is a "chimeric" antibody, part mouse and part human. That detail may matter later, because the immune system can make antibodies against infliximab. The label also notes that people who had a drug-free gap of more than 16 weeks showed a higher rate of antibodies than those dosed steadily.

Infliximab is one of several biologic classes used in Crohn's. Others include adalimumab (also an anti-TNF, given by injection), vedolizumab, and the IL-12/23 and IL-23 drugs. We compare how the infused ones feel on the day in what to expect at your first biologic infusion, and this post stays on infliximab.

Which versions of infliximab exist?

Remicade is the original brand. Biosimilars (for example Inflectra) are separately manufactured versions approved as highly similar. There is also Zymfentra, an infliximab-dyyb product given under the skin. Its US label limits it to maintenance after you have completed IV induction with an infliximab product (Zymfentra label). We return to both below.

Does Remicade work for Crohn's disease? What the trials show

Yes, for a substantial share of people with moderate to severe Crohn's. In ACCENT I, 335 of 573 people (58%) responded to a single infusion within 2 weeks, and at week 30 remission was 21% on placebo versus 39% and 45% on two repeat-infusion schedules (Hanauer 2002).

The table gathers the landmark trials in one place. Percentages are as published in each paper's abstract.

TrialWhoWhat it showed
ACCENT I (2002)573 adults with active Crohn'sWeek 30 remission 21% placebo, 39% and 45% repeat infusions; median time to loss of response 19 weeks vs 38 and over 54 weeks (Hanauer 2002)
Fistula trial (1999)94 adults with draining fistulasAt least 50% fewer draining fistulas in 68% (lower dose) and 56% (higher dose) vs 26% placebo; all fistulas closed in 55% and 38% vs 13% (Present 1999)
ACCENT II (2004)306 adults with fistulasTime to loss of response over 40 weeks with maintenance vs 14 weeks with placebo (Sands 2004)
SONIC (2010)508 adults, new to immunomodulators and biologicsSteroid-free remission at week 26: 56.8% combination, 44.4% infliximab alone, 30.0% azathioprine alone (Colombel 2010)
Early combined immunosuppression (2008)133 adults, newly diagnosedRemission without steroids or surgery at week 26: 60.0% vs 35.9% with conventional step-up (D'Haens 2008)

What do the fistula results mean in plain English?

Fistulas are one of the places where infliximab stands out. In the first fistula trial, closure of every fistula happened in 55% of people on the lower dose against 13% on placebo, but the median time fistulas stayed closed was only about three months (Present 1999). ACCENT II then showed that continuing infusions every 8 weeks extended the response (Sands 2004).

The AGA guideline recommends infliximab over no treatment for induction and maintenance of fistula remission in people with active perianal fistulas, and says adding ciprofloxacin to an anti-TNF improved fistula closure in the studies it reviewed (Feuerstein 2021). Surgery, such as seton placement, often runs alongside medicine. If you want to understand the symptom side, see our post on what a perianal fistula feels like.

How good is the evidence, honestly?

Strong, with limits. These were trials in selected people with moderate to severe disease, they ran for 1 to 2 years, and many of the headline numbers are about reaching remission, not about staying there for a decade. In real-world UK data (the PANTS cohort), only about a third of people with active luminal Crohn's on an anti-TNF were in remission at the end of 3 years: 34.7% for infliximab (Chanchlani 2024).

Both facts are true at once. In a trial, infliximab clearly beats placebo. In ordinary practice, a large share of people either do not respond or lose response, which is why the later sections on antibodies and drug levels matter.

What are the pros of Remicade for Crohn's disease?

The pros are the strength of the evidence, its effect on fistulas, its ability to reduce steroid use, and a long track record. Specific, sourced points:

  • It treats the cause of the inflammation, not just the symptoms. In an ACCENT I endoscopy substudy summarized on the label, mucosal healing at week 10 was seen in 13 of 43 people on infliximab versus 1 of 28 on placebo (Remicade label). That is a small subgroup, so treat it as a signal.
  • It helps people come off steroids. In ACCENT I, among people in remission who were taking steroids at the start, more on repeat infusions were able to stop them than on placebo (the label gives 25% and 34% versus 11% at week 54).
  • It has randomized fistula data. Few other options have this, and the AGA gives infliximab a strong recommendation for perianal fistulas (Feuerstein 2021).
  • Infusions come with built-in supervision. Because a nurse administers it, it is not a daily task. People in r/CrohnsDisease often say the 2-hour chair time is the price, and that being cared for at the unit is a plus.
  • It has the longest safety record. The TREAT registry followed thousands of people for about 5 years (more below).
  • Biosimilars widen access. Several approved biosimilar versions exist alongside the original.

What do people in r/CrohnsDisease say about the upside?

Reading the three main threads for this question (Remicade pros and cons, experience with Remicade and what to expect with Remicade), a few themes come up repeatedly. People who have been on it for many years often describe it as steady, with the main cost being the time spent in the infusion chair. Several describe feeling much better within days or weeks of the first doses. Others describe wanting a treatment that works before complications such as strictures, abscesses or surgery develop. These are personal accounts, not evidence, but they show what the benefit feels like to the people who get it.

What are the cons and risks of Remicade?

The cons are the boxed warning (serious infections and malignancy), infusion reactions, other label warnings, the practical burden of infusions, and the chance of losing response. The US label opens with a boxed warning for serious infections and malignancy (Remicade label). Here is what each part says and how to read it.

How serious are the infection risks?

The label says people on Remicade have an increased risk of serious infections that can lead to hospitalization or death, including tuberculosis (TB), bacterial sepsis and invasive fungal infections such as histoplasmosis. It adds that most people who developed these infections were also taking immunosuppressants such as methotrexate or corticosteroids. It asks for latent TB testing before and during treatment, and hepatitis B testing before starting (Remicade label).

To put numbers on it, the label reports treated infections in 36% of Remicade-treated patients (average 51 weeks of follow-up) versus 25% on placebo in its clinical studies. Those are all infections needing treatment, most of them minor. For Crohn's specifically, the TREAT registry followed 6,273 people for a mean of 5.2 years. Mortality was similar with and without infliximab (0.58 versus 0.59 per 100 patient-years), but serious infection was higher with infliximab (hazard ratio 1.43), and moderate to severe disease activity (1.57 for prednisone, 2.24 for disease activity) carried even higher risk (Lichtenstein 2012).

That second point is easy to miss. Untreated, active Crohn's, and steroids used to control it, are risk factors for infection in their own right. People on r/CrohnsDisease make this argument often, noting that uncontrolled inflammation and repeated courses of other medicines carry risks too. TREAT was observational, so this comparison cannot fully separate drug from disease severity.

What about lymphoma and other cancers?

The boxed warning says lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers. It also describes postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL), a rare cancer. Almost all of those cases had also taken azathioprine or 6-mercaptopurine, and most Remicade cases were in people with Crohn's or ulcerative colitis, most of them adolescent or young adult males (Remicade label).

For adults, the best large estimate comes from a French nationwide cohort. Lymphoma rates per 1,000 person-years were 0.26 with neither drug, 0.54 on a thiopurine alone, 0.41 on an anti-TNF alone, and 0.95 on combination. The adjusted hazard ratios were 2.60, 2.41 and 6.11 versus neither (Lemaitre 2017). In absolute terms, 0.41 per 1,000 person-years is about 4 cases per 10,000 people a year. The authors called the added risk small but significant, higher with combination than either alone.

The label also lists skin cancers (melanoma and Merkel cell carcinoma) and recommends periodic skin examination, especially if you have risk factors.

What about infusion reactions?

In the label's clinical studies about 20% of Remicade-treated patients had an infusion reaction (any event during or within an hour after an infusion) versus about 10% on placebo (Remicade label). Most are mild, such as flushing, headache or itching. Serious reactions are uncommon and the unit is set up to treat them, with the infusion slowed or stopped. Delayed reactions with fever, rash or aches can appear days later.

People in r/CrohnsDisease report a range of experiences. Some describe never having an issue in a decade or more, and some describe developing hives or a rash and moving to a different drug. For the day itself, including premedication, see our first infusion guide.

What other warnings are on the label?

Beyond infections and cancer, the label lists:

  • Hepatitis B reactivation in carriers, sometimes fatal, which is why testing comes first.
  • Hepatotoxicity, with severe liver reactions reported, some needing transplant.
  • Heart failure: new or worsening symptoms can occur, and higher doses are contraindicated in moderate or severe heart failure.
  • Cytopenias, meaning low blood cell counts.
  • A lupus-like syndrome, with treatment stopped if symptoms follow.
  • Live vaccines are not to be given with it, and the label asks that you be brought up to date with vaccinations beforehand.

This is why routine bloods are part of the deal, which we explain in why you need blood tests on a biologic.

Is Remicade an immunosuppressant, and is it hard on the body?

Yes, it suppresses part of your immune system, because blocking TNF removes one of its signals. But it is targeted, unlike steroids, which act broadly. Many people in r/CrohnsDisease say they get sick no more often than before, and others describe taking extra hygiene steps. Either can be true, because individual and infection-type differences are large.

The evidence supports a measured reading. Serious infections are more likely, while everyday infections are mostly manageable, and the label's testing, vaccination and monitoring steps exist to catch the dangerous ones. Practical habits people mention include handwashing, being careful with public pools and hot tubs, and telling the team early about fever. We cannot assess any of these as evidence, so treat them as common-sense tips to check with your nurse.

Day to day, the commonest complaint is tiredness around infusion day. We could find no study that measured it, but it appears across threads, and it overlaps with the fatigue many people have anyway (see Crohn's fatigue in remission).

Remicade with azathioprine: is combination therapy better?

For people new to both drug types, the evidence says combination usually works better, and it carries added risks. In SONIC, steroid-free remission at week 26 was 56.8% on infliximab plus azathioprine, 44.4% on infliximab alone and 30.0% on azathioprine alone. Mucosal healing at week 26 was 43.9% versus 30.1% (P = 0.06) versus 16.5%, and serious infections were 3.9%, 4.9% and 5.6% (Colombel 2010).

The AGA suggests infliximab with a thiopurine over infliximab alone for adults who are new to both biologics and immunomodulators (a conditional recommendation, moderate certainty). It also notes that the benefit might be partly achievable through drug-level monitoring, without the added risk and inconvenience (Feuerstein 2021).

Why does combination help?

A main reason is antibodies. In PANTS, antibodies linked to undetectable drug levels developed in an estimated 44.0% of infliximab-treated people by year 3, and having an immunomodulator alongside was associated with far fewer (hazard ratio 0.40) (Chanchlani 2024).

What is the trade-off?

The lymphoma data above show the higher risk with combination (adjusted hazard ratio 6.11 versus neither drug), and the label's HSTCL warning applies mostly to people also on azathioprine or 6-mercaptopurine (Lemaitre 2017; Remicade label). Whether to combine, for how long, and with which drug depends on your age, sex, previous exposure and disease. That is the single most individual conversation to have with your gastroenterologist.

Why do some people lose response to Remicade?

Because the body can clear the drug too fast, usually by making antibodies to it, or because inflammation drives on through a route TNF does not control. In PANTS, among initial responders, the estimated proportion who had lost response by years 1, 2 and 3 was 34.4%, 54.5% and 60.0% for infliximab (Chanchlani 2024).

The same study found low drug concentration at week 14 predicted later loss of response, and that obesity, female sex and thiopurine dose also played a part. The label puts antibody rates in Crohn's at about 10% over 1 to 2 years under steady dosing, and says the figure depends heavily on the assay used. PANTS measured something different (antibodies with undetectable drug levels, over 3 years), so the two figures are not directly comparable.

What is drug-level testing, and does it help?

Therapeutic drug monitoring means measuring how much infliximab is in your blood just before a dose (a trough level), and sometimes checking for antibodies. In the TAXIT trial of 263 people with Crohn's or ulcerative colitis, 93% of the people who started above the 3 to 7 micrograms per mL target range reached it after a dose reduction, which cut drug cost by about 28% in that group. But the primary comparison found continued concentration-based dosing was not superior to clinically based dosing for remission at 1 year, although it was associated with fewer flares (Vande Casteele 2015).

So the evidence is mixed: testing is useful for working out why a drug is failing, with less clear proof as a routine tool. Our post on what it means when a biologic stops working walks through how teams read the results, and the blood tests post explains what is being checked at each visit. Dose or interval changes are always your team's call.

What happens if it stops working?

Options a team may weigh include optimizing the same drug, adding an immunomodulator, or moving to another drug. The AGA recommends ustekinumab for people who never responded to an anti-TNF, and adalimumab or ustekinumab for people who responded to infliximab and then lost response (Feuerstein 2021). One person's Remicade stopping is not a failure of the whole class of drugs.

Is a Remicade biosimilar as good as Remicade?

In the Crohn's trials we reviewed, yes. A phase 3 trial of 220 biologic-naive people with active Crohn's found the biosimilar CT-P13 non-inferior to Remicade: 69.4% versus 74.3% had a CDAI drop of 70 points or more at week 6 (Ye 2019).

The second major trial, NOR-SWITCH, looked at people already stable on the original who were randomized to switch or stay. Disease worsening happened in 26% staying on the original and 30% switching, within the pre-set margin for non-inferiority. The authors state it was not powered to show non-inferiority in individual diseases, and only 32% of participants had Crohn's (Jørgensen 2017).

What that means for you: biosimilars have solid evidence and are common in practice, but "not worse overall" is not the same as "proven identical in your disease". If you are asked to switch, it is reasonable to ask how your response will be followed afterwards and what happens if things change.

What about the subcutaneous version?

The Zymfentra label restricts it to adults who have finished IV induction with an infliximab product, as maintenance only, with the first injection replacing the next scheduled infusion for people already on IV maintenance (Zymfentra label). Whether you are a candidate, and how any switch is monitored, is for your team and your insurer. We have not reviewed trial data for it here, so we do not compare its results with infusions.

What is it like day to day on Remicade?

Practically, it is a time commitment: maintenance every 8 weeks, with each visit commonly taking a few hours, and the first one longest. People in r/CrohnsDisease describe long-term users planning their schedule around infusion day, for example booking a Friday afternoon so they can rest, bringing a blanket because the infusion room feels cold, and being a bit tired that evening. For a full walk-through, see what to expect at your first biologic infusion.

Other practical points:

  • Work and travel. Infusion days and the exact intervals matter for planning. Our posts on keeping a job with Crohn's and flying with Crohn's medication cover the logistics.
  • Infections. Tell your team promptly about fever or signs of infection, as the label says treatment should be reviewed if a serious infection develops.
  • Vaccines. The label asks for vaccinations to be brought up to date before starting and says live vaccines should not be given during treatment.
  • Pregnancy. The label says that babies exposed to infliximab in the womb should wait at least six months after birth before live vaccines. Planning belongs with your IBD and obstetric teams, and our guide to pregnancy with Crohn's lists what to ask.
  • Cost and coverage differ by country and plan. This guide uses US labels and evidence. Ask your clinic or pharmacist how infusions are billed and whether the original or a biosimilar is covered.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Is Remicade the best treatment for Crohn's disease?

It is among the best studied, but no drug is best for everyone. The AGA recommends anti-TNF drugs (infliximab and adalimumab with moderate-certainty evidence) over no treatment for moderate to severe Crohn's, and says infliximab, adalimumab or ustekinumab are preferred over certolizumab pegol in people new to biologics (Feuerstein 2021). For how infliximab sits next to adalimumab, ustekinumab, vedolizumab and the newer classes, see which biologic is best for Crohn's disease.

That is a recommendation for a class, not a ranking of one named drug above all the others for each person. The guideline's own comments say the choice should be shaped by things such as previous drug exposure, type of failure, disease features and preference.

What is the safest biologic for Crohn's disease?

There is no trial that answers that cleanly. Separate trials enrolled different people and measured safety in different ways, so comparing percentages between them is unreliable. Infliximab's risks are unusually well documented because it has been used the longest, and that is not the same as being riskier. A fair question for your team is how each option's label warnings apply to your age, infection history, other illnesses, planned pregnancy and other medicines.

What about people who would rather avoid biologics?

Some people in the Reddit threads said they were wary of lowering their immune system, especially when their symptoms felt mild. That is understandable, and the honest answer is that Crohn's can progress silently. The point made repeatedly by others was that inflammation can cause strictures, fistulas and abscesses before symptoms are severe, and that choosing to treat is not a bet against risk but a choice between two kinds of risk. We do not recommend a choice either way. What helps is bringing your specific worries to your gastroenterologist: your scan or scope findings, your family and work context, and what you are willing to accept.

What questions should you ask your gastroenterologist about Remicade?

Good questions turn a pros-and-cons list into a decision made with you. Consider asking:

  1. What does my disease look like on scope, scan or imaging, and why is a biologic being suggested now?
  2. Would you suggest infliximab alone or with an immunomodulator, and for how long?
  3. Is the original or a biosimilar being used, and would I be switched later?
  4. What infection, vaccine and cancer screening should I have before starting and while on it?
  5. How will we know it is working, and when will you check drug levels and antibodies?
  6. What happens if it stops working, or I react to it?
  7. How should my infusion schedule fit with work, travel and any pregnancy plans?
  8. What should I do if I get a fever or infection between infusions?

The longer list in questions to ask about Crohn's treatment is a good companion.

When should you contact your IBD team promptly?

Contact your IBD team promptly or seek urgent care for fever or signs of infection, a persistent cough with night sweats or weight loss, hives, swelling or breathlessness during or after an infusion, yellowing of the skin or eyes, new swelling of your legs or shortness of breath, or new or changing skin lesions. These come straight from the label's warnings: infection, TB, hepatotoxicity, heart failure and skin cancer.

A flare of your usual Crohn's symptoms between infusions also deserves a call rather than waiting for the next one. Our guide on how to tell if you are in a Crohn's flare covers what to watch. Blood in the stool, unexplained weight loss, fever, or night-time symptoms always need a doctor's attention promptly.

How can you track whether Remicade is working?

Log your symptoms and energy around each infusion date, so you and your team can see how response holds between doses. Patterns such as symptoms creeping back in the last weeks before an infusion are exactly what a team wants to know about when considering drug levels, interval or other options.

Useful things to note: stool frequency and consistency, abdominal pain, urgency, fistula drainage, energy, any missed or delayed infusions, antibiotics, steroid courses, and any fever or infection. A notebook works. If you prefer an app, Clairop lets you log medications alongside symptoms and stools and builds a one-page summary for appointments; you can see how it works on the how it works page, or browse the best apps for Crohn's disease. It does not diagnose or interpret drug levels, and your team makes the clinical decisions.

What are the common myths about Remicade?

Four ideas come up often, and each is only partly right.

"Once you start, you are on it for life." Some people remain on it for years and some stop for reasons such as side effects, loss of response or sustained remission. The label notes that antibodies are more common after drug-free gaps, so decisions about pausing belong with your team.

"It wrecks your immune system." It does suppress part of it, and the boxed warning is serious, but TREAT found mortality similar with and without infliximab, and untreated active disease and steroids carry their own infection risks (Lichtenstein 2012).

"If it fails, nothing else will work." Guidelines list several other options after an anti-TNF stops working, including ustekinumab and adalimumab, depending on the type of failure (Feuerstein 2021).

"Biosimilars are a cheap, weaker copy." In the Crohn's trial reviewed, response rates were within the pre-set non-inferiority margin (Ye 2019), while acknowledging the NOR-SWITCH limit on disease-specific power.

Frequently asked questions

Is Remicade good for Crohn's disease?
For many people with moderate to severe Crohn's, yes. In ACCENT I, 39% to 45% of people who responded to a first infusion were in remission at week 30 on repeat infusions, against 21% on placebo. It also has trial evidence in fistulas. It does not work for everyone, and benefit has to be weighed against the label's infection and lymphoma warnings.
Is Remicade an immunosuppressant?
Yes, in the sense that it blocks tumor necrosis factor (TNF), a signaling protein in your immune system, so it suppresses part of that response. It is a targeted biologic rather than a broad drug like a steroid or azathioprine, but the US label still carries a boxed warning for serious infections and malignancy.
Is Remicade hard on the body?
Most people tolerate it, and many report tiredness on infusion day as the main nuisance. The label lists infusion reactions, infections, liver problems, heart failure warnings and rare cancers. In the TREAT registry, mortality was similar with and without infliximab, though serious infections were more common with it.
How long are people usually on Remicade?
There is no single answer. Some people report decades of good control, while in the UK PANTS study about 60% of infliximab responders had lost response by year 3. Some stop because of side effects or antibodies, others because the disease has been quiet. Duration is an individual decision with your IBD team.
What are the biggest risks of Remicade for Crohn's disease?
The label's boxed warning names serious infections (including tuberculosis, invasive fungal infections and sepsis) and malignancy, including a rare fatal lymphoma called hepatosplenic T-cell lymphoma, mostly in young males also taking azathioprine or 6-mercaptopurine. Infusion reactions, hepatitis B reactivation and liver injury are also on the label.
Is Remicade the best treatment for Crohn's disease?
It is one of the best studied, and the AGA recommends anti-TNF drugs over no treatment for moderate to severe Crohn's and recommends infliximab for perianal fistulas. But no single drug is best for everyone. The choice depends on your disease pattern, previous treatments, other conditions and preferences, and it belongs to you and your gastroenterologist.
What is the safest biologic for Crohn's disease?
No head-to-head trial has settled this, and comparisons between separate trials are unreliable because the populations differ. Infliximab has the longest follow-up, including registry data to 5 years, which cuts both ways: more is known about its risks. Ask your team how each option's label risks apply to your age, infections history and other medicines.
Is a Remicade biosimilar as good as the original?
In the trials we reviewed, yes. A phase 3 Crohn's trial found the biosimilar CT-P13 non-inferior to Remicade for early response (69.4% vs 74.3%), and NOR-SWITCH found switching from the original was non-inferior overall. NOR-SWITCH was not powered to prove it in Crohn's alone, so ask your team about your own situation.
Does Remicade help Crohn's fistulas?
It has randomized evidence for draining fistulas. In the first trial, 68% of people on the lower dose had at least a 50% drop in draining fistulas, against 26% on placebo, and in ACCENT II continued infusions lengthened time to loss of response. Fistulas can return, so the AGA also describes adding antibiotics or surgery in some cases, decided by your team.
Can I stay on Remicade during pregnancy?
That is a decision for you, your gastroenterologist and your obstetric team before and during pregnancy, not something to change on your own. The US label notes that babies exposed in the womb should wait at least six months after birth for live vaccines. Our Crohn's and pregnancy guide explains the questions to raise.
What is the best way to track whether Remicade is working?
Clairop, because it lets you log symptoms, stools and medications together and turns them into a one-page report with your score trend and medication adherence. Note energy and symptoms against each infusion date so you can show your team how response holds between doses. It is iPhone only and free to download; your team interprets it.
Should I stop Remicade if I am worried about the side effects?
Not on your own. Stopping and restarting infliximab can bring its own problems, including a higher rate of antibodies after drug-free gaps of more than 16 weeks, according to the label. If side effects or fear are weighing on you, tell your IBD team, who can review your risks, drug levels and alternatives with you.

Sources

  1. Janssen Biotech Inc. REMICADE (infliximab) prescribing information. DailyMed, US National Library of Medicine. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257
  2. Celltrion USA Inc. ZYMFENTRA (infliximab-dyyb) prescribing information. DailyMed, US National Library of Medicine. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a193ab-9f96-4da6-aa7c-31212e81879a
  3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9. doi:10.1016/S0140-6736(02)08512-4
  4. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340(18):1398-405. doi:10.1056/NEJM199905063401804
  5. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876-85. doi:10.1056/NEJMoa030815
  6. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-95. doi:10.1056/NEJMoa0904492
  7. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-7. doi:10.1016/S0140-6736(08)60304-9
  8. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409-22. doi:10.1038/ajg.2012.218
  9. Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679-86. doi:10.1001/jama.2017.16071
  10. Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterol Hepatol. 2024;9(6):521-38. doi:10.1016/S2468-1253(24)00044-X
  11. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320-9. doi:10.1053/j.gastro.2015.02.031
  12. Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304-16. doi:10.1016/S0140-6736(17)30068-5
  13. Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699-707. doi:10.1016/S0140-6736(18)32196-2
  14. Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021;160:2496-508. doi:10.1053/j.gastro.2021.04.022

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools